Piper Affirms Inovio Pharma (INO) at 'Overweight' Amid Increasingly Visible Clinical Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Piper Affirms Inovio Pharma (INO) at 'Overweight' Amid Increasingly Visible Clinical Progress
August 8, 2016 8:00 AM EDT
PLYMOUTH MEETING, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended June 30, 2016. The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Total revenue was $6.2 million compared to $5.3 million. Total operating expenses were $24.4 million compared to $20.4 million. The net loss attributable to common stockholders was $18.7 million, or $0.26 per share, compared to $6.2 million, or $0.09 per share.
Revenue
The increase in revenue was primarily due to an increase in development payments from our DARPA Ebola... More
August 4, 2016 8:02 AM EDT
PLYMOUTH MEETING, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing Inovios regulatory strategies, including leadership over regulatory submissions, regulatory compliance, advertising and promotion review, and registrations to support Inovios product pipeline. Â Â
Dr. J. Joseph Kim, Inovios President & CEO, said, Ami has shown technical excellence and leadership in successfully moving our DNA-based... More
